Jaguar’s Canalevia-CA1 Normalizes Dog Chemotherapy Diarrhea in Three Days with 83% Success
Canalevia-CA1 dosing in chemotherapy-induced diarrhea trial normalized daily stool in dogs within three days, with 83% of owners reporting effective treatment and 40% complete resolution. Results compare to 12.5% spontaneous improvement and will support Jaguar’s filing for full FDA approval.
1. Topline Trial Results
Jaguar Health completed its pivotal effectiveness trial of Canalevia-CA1 125 mg administered twice daily in dogs undergoing chemotherapy, achieving statistically significant normalization of daily stool consistency within three days of treatment.
2. Owner Survey Outcomes
An end-of-study owner survey showed 83% of respondents rated Canalevia-CA1 as effective for managing chemotherapy-induced diarrhea and 40% reported complete symptom resolution, compared to a 12.5% improvement rate in untreated dogs.
3. Regulatory Submission Plans
Jaguar plans to file full trial data in its Animal Drug Application to secure complete FDA approval for Canalevia-CA1 and will submit the results for scientific publication to support wider veterinary adoption.
4. Safety Profile
Canalevia-CA1 is conditionally approved for canine use with common adverse reactions including decreased appetite, reduced activity, dehydration, abdominal pain and vomiting, and is restricted to use under veterinary prescription by federal law.